dismiss

The 1st Ever Medical World Americas is in Houston, TX, April 28-30 - Get a Free 1-Day Pass!

SEARCH

Current Location: DOTmed News > Industry Headlines > This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Industry Headlines

Doc fix bill puts clinical decision support in the spotlight Appropriateness criteria is the new reality.

False positive results: not as bad as you thought But women will still undergo additional breast cancer tests.

ECRI's top 10 patient safety concerns HIT, care coordination, drug shortages top safety list.

FDA clears new CT system from Siemens Ideal for challenging cases.

FDA OKs Shimadzu's new R/F system For a wide variety of exams.

Gov. Jan Brewer signs breast density law Arizona becomes the latest state with inform legislation.

CT can detect arterial plaque for diabetics CCTA is a welcome development.

Goggles that illuminate cancer cells Could they reduce second surgeries?

Philips suspends CT and PET/CT production at Ohio facility Setback for customers and the company.

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

Hologic wraps up $3.8 billion Gen-Probe buy

by Brendon Nafziger , DOTmed News Associate Editor
Hologic said Wednesday that it wrapped up its nearly $3.8 billion cash purchase of molecular diagnostics company Gen-Probe Inc., in line with the company's earlier projections.

On an earnings call this week, the publicly traded women's health medical device company indicated that it expected the deal, first announced in April, to finish by Aug. 1.

Story Continues Below Advertisement

We want to buy your Siemens Symphony or Avanto MRI -- today!

Top Dollar Paid, Fixed or Mobile. Call our Siemens Specialist for a Quote today -- 212-558-6600 Ext. 250



Gen-Probe, based in San Diego, makes tests for STDs and the West Nile Virus, among other conditions.

Gen-Probe's shareholders voted to approve the transaction on Tuesday. Shareholders will receive $82.75 in cash for each share.

Hologic expects the deal to add 20 cents to its adjusted earnings per share for the next fiscal year. The Bedford, Mass.-based company also hopes to realize $75 million in "cost synergies" over the next three years.

This week, while announcing third quarter financial results, Hologic also revealed that it was nearly halfway to its sales goal for its 3-D mammography system, the first of its kind cleared for sale in the United States.


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED